MX2020008044A - Células asesinas naturales resistentes al factor de crecimiento transformante beta. - Google Patents
Células asesinas naturales resistentes al factor de crecimiento transformante beta.Info
- Publication number
- MX2020008044A MX2020008044A MX2020008044A MX2020008044A MX2020008044A MX 2020008044 A MX2020008044 A MX 2020008044A MX 2020008044 A MX2020008044 A MX 2020008044A MX 2020008044 A MX2020008044 A MX 2020008044A MX 2020008044 A MX2020008044 A MX 2020008044A
- Authority
- MX
- Mexico
- Prior art keywords
- natural killer
- cells
- killer cells
- growth factor
- transforming growth
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 abstract 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000049939 Smad3 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623682P | 2018-01-30 | 2018-01-30 | |
| PCT/US2019/015617 WO2019152387A1 (fr) | 2018-01-30 | 2019-01-29 | Transformation de cellules tueuses naturelles résistantes au facteur de croissance bêta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008044A true MX2020008044A (es) | 2020-12-10 |
Family
ID=67478491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008044A MX2020008044A (es) | 2018-01-30 | 2019-01-29 | Células asesinas naturales resistentes al factor de crecimiento transformante beta. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200368281A1 (fr) |
| EP (1) | EP3746118A4 (fr) |
| JP (1) | JP2021512164A (fr) |
| KR (1) | KR20200118449A (fr) |
| CN (1) | CN111818941A (fr) |
| AU (1) | AU2019213678A1 (fr) |
| BR (1) | BR112020015490A2 (fr) |
| CA (1) | CA3090096A1 (fr) |
| IL (2) | IL276374B2 (fr) |
| MX (1) | MX2020008044A (fr) |
| RU (1) | RU2020127722A (fr) |
| SG (1) | SG11202007288VA (fr) |
| WO (1) | WO2019152387A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4117687A1 (fr) * | 2020-03-11 | 2023-01-18 | Research Institute at Nationwide Children's Hospital | Cellules nk et leurs utilisations pour le traitement d'infections microbiennes |
| CN115697355A (zh) * | 2020-04-30 | 2023-02-03 | 全国儿童医院研究所 | 用抗TGF-β的NK细胞克服免疫抑制 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2058388A1 (fr) * | 2007-10-05 | 2009-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cellules NKT non conventionnelles pour une utilisation dans le traitement contre le cancer |
| CN105143441B (zh) * | 2014-01-13 | 2019-11-08 | 张明杰 | 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法 |
| JP7049830B2 (ja) * | 2014-10-27 | 2022-04-07 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド | ナチュラルキラー細胞のための方法及び組成物 |
| JP2018526013A (ja) * | 2015-09-01 | 2018-09-13 | イネイト・テューマー・イミュニティ・インコーポレイテッドＩｎｎａｔｅ Ｔｕｍｏｒ Ｉｍｍｕｎｉｔｙ， Ｉｎｃ． | 免疫または免疫抑制性サイトカインに対する抵抗性が増大した免疫細胞およびその使用 |
| CN108697734B (zh) * | 2015-09-14 | 2023-04-18 | 明尼苏达大学董事会 | 表现出适应性表型的nk细胞以及制备和使用方法 |
-
2019
- 2019-01-29 MX MX2020008044A patent/MX2020008044A/es unknown
- 2019-01-29 BR BR112020015490-3A patent/BR112020015490A2/pt unknown
- 2019-01-29 AU AU2019213678A patent/AU2019213678A1/en active Pending
- 2019-01-29 IL IL276374A patent/IL276374B2/en unknown
- 2019-01-29 JP JP2020562093A patent/JP2021512164A/ja active Pending
- 2019-01-29 CN CN201980016864.3A patent/CN111818941A/zh active Pending
- 2019-01-29 IL IL309656A patent/IL309656A/en unknown
- 2019-01-29 US US16/966,367 patent/US20200368281A1/en active Pending
- 2019-01-29 WO PCT/US2019/015617 patent/WO2019152387A1/fr unknown
- 2019-01-29 KR KR1020207024676A patent/KR20200118449A/ko not_active Application Discontinuation
- 2019-01-29 EP EP19747119.6A patent/EP3746118A4/fr active Pending
- 2019-01-29 RU RU2020127722A patent/RU2020127722A/ru unknown
- 2019-01-29 SG SG11202007288VA patent/SG11202007288VA/en unknown
- 2019-01-29 CA CA3090096A patent/CA3090096A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019213678A1 (en) | 2020-09-03 |
| BR112020015490A2 (pt) | 2021-03-23 |
| EP3746118A1 (fr) | 2020-12-09 |
| US20200368281A1 (en) | 2020-11-26 |
| JP2021512164A (ja) | 2021-05-13 |
| CA3090096A1 (fr) | 2019-08-08 |
| IL276374A (en) | 2020-09-30 |
| IL276374B2 (en) | 2024-05-01 |
| RU2020127722A (ru) | 2022-02-28 |
| SG11202007288VA (en) | 2020-08-28 |
| KR20200118449A (ko) | 2020-10-15 |
| CN111818941A (zh) | 2020-10-23 |
| WO2019152387A1 (fr) | 2019-08-08 |
| IL276374B1 (en) | 2024-01-01 |
| IL309656A (en) | 2024-02-01 |
| EP3746118A4 (fr) | 2021-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551241A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
| MX2018008266A (es) | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer. | |
| EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
| PH12020551151A1 (en) | Method of producing natural killer cells and composition for treating cancer | |
| MX2020008044A (es) | Células asesinas naturales resistentes al factor de crecimiento transformante beta. | |
| RU2016103614A (ru) | Способы получения т-клеток против антигена папилломавируса человека | |
| MX2022002143A (es) | Celulas inmunitarias para terapias celulares adoptivas. | |
| IN2014DN09956A (fr) | ||
| BR112018072701A2 (pt) | métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais | |
| BR112018010499A2 (pt) | método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células | |
| EP4103303A4 (fr) | Dispositif de récupération d'eau atmosphérique à rendement élevé, et procédés d'utilisation de celle-ci | |
| CO2022013055A2 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| NZ587598A (en) | Methods of increasing proliferation of a cell by administering a low magnitude, high frequency mechanical signal | |
| EP4269595A3 (fr) | Méthodes d'expansion sélective de cellules exprimant un tcr avec une région constante murine | |
| RU2012150147A (ru) | Метод иммунотерапии онкологических заболеваний и фармацевтические композиции на основе онкологического вируса сендай | |
| EP3971285A3 (fr) | Compositions de cellules dendritiques activées et traitements immunothérapeutiques pour des sujets atteints de cancers avancés | |
| De Maria et al. | Revisited function of human NK cell subsets | |
| BR112021017651A2 (pt) | Mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer | |
| WO2021242869A3 (fr) | Cellules immunitaires d'ingénierie, compositions et procédés associés | |
| AU2003260452A1 (en) | Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells | |
| JOP20210025A1 (ar) | تركيبات وطرق للتنشيط المتحكم فيه للمبيض | |
| LI et al. | Effects of light intensity on biological characteristics, physiological indexes and flavone content of Kalimeris indica | |
| WO2023239710A8 (fr) | Benzopyrimidin-4 (3h)-ones en tant qu'inhibiteurs de pi3k | |
| RU2013158429A (ru) | Способ индукции противоопухолевого цитотоксического иммунного ответа с помощью дендритных клеток, трансфицированных рнк опухолевых клеток, против клеток рака молочной железы |